ArticleESC heart failure2025
Prognostic role of TAPSE to PASP ratio in outpatients with left ventricular systolic dysfunction.
Article in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- The predictive value of the TAPSE/PASP ratio for major adverse cardiovascular events in patients with chronic heart failure: evidence from a prolonged follow-up cohort.Annals of medicine · 2026Article
- Associations between cardiometabolic traits and diabetic cardiomyopathy: an imaging-based analysis.Acta diabetologica · 2026Article
- Interaction of secondary ventricular tricuspid regurgitation with RV in HFREF: an invasive pressure-volume loop study.ESC heart failure · 2026Article
- Postoperative Right Ventriculo-Pulmonary Artery Coupling Assessed by TAPSE/PASP as a Predictor of Long-Term Outcomes After TAVI.Anatolian journal of cardiology · 2026Article
- Prognostic significance of right ventricular-pulmonary artery coupling assessed by TAPSE/PASP ratio in patients with HFmrEF.Heart and vessels · 2026Article
- Development, Validation, and Subtype Analysis of a Predictive Model for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy.Reviews in cardiovascular medicine · 2025Article
- Impact of Gliflozins on Right Heart Remodeling in Italian Patients with Type 2 Diabetes and Heart Failure: Results from the GLISCAR Real-World Study.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Prognostic role of TAPSE to PASP ratio in outpatients with left ventricular systolic dysfunction.ESC heart failure · 2025Article
- Association between the TAPSE/PASP ratio and exercise capacity in heart transplant candidates with advanced heart failure.Frontiers in cardiovascular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsFew data are available regarding the role of tricuspid annulus plane systolic excursion to pulmonary artery systolic pressure (TAPSE/PASP), a measurement of right ventricular to pulmonary artery coupling, in patients with chronic heart failure and left ventricular systolic dysfunction. METHODS AND
resultsThis retrospective single-centre study included outpatients with left ventricular systolic dysfunction (ejection fraction ≤ 50%) evaluated between January 2022 and December 2022. TAPSE/PASP was evaluated as a continuous variable and as tertiles according to its value on the first visit. The primary outcome of the study was a composite of all-cause mortality or heart failure (HF) events at the last available follow-up.
resultsA total of 642 patients were included (mean age 71 ± 13 years, 78% male, mean left ventricular ejection fraction 40% [interquatile range 35-46]). Patients with lower TAPSE/PASP had more co-morbidities (i.e., atrial fibrillation, chronic kidney disease or previous cardiovascular implantable electronic device), an higher New York Heart Association class (P < 0.001), more signs of congestion (P = 0.007), and had more probability to receive intravenous furosemide during the visit (P < 0.001). After a median follow-up of 474 days [interquartile range 392-507 days], a total of 51 patients (8.0%) died (with 24 patients [3.8%] experiencing cardiovascular-related deaths), a total of 179 patients (28.1%) experienced a composite outcome, and 158 patients (24.8%) had HF events. Kaplan-Meier analysis showed that the estimated 1-year rate of the primary outcome was higher in the lowest tertile (38.0%), as compared with the intermediate (19.6%) and highest tertiles (14.9%; P-value log-rank <0.001). TAPSE/PASP ratio as a continuous variable was independently associated with the primary outcome (adjusted hazard ratio for 0.1 mm/mmHg increase 0.91, 95% CI 0.84-0.98, P = 0.009), predominantly driven by a higher risk of HF events during follow-up. Analysing the impact of TAPSE/PASP tertiles on the primary outcome, an independent associated was confirmed at multivariate analisys for the highest versus lowest tertile (adjusted hazard ratio 0.61, 95% CI 0.38-0.99, P = 0.044).
conclusionsTAPSE/PASP was independently associated with mortality or HF events among ambulatory patients with left ventricular systolic dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.